1. Home
  2. AVTX vs SKYE Comparison

AVTX vs SKYE Comparison

Compare AVTX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVTX
  • SKYE
  • Stock Information
  • Founded
  • AVTX 2011
  • SKYE 2012
  • Country
  • AVTX United States
  • SKYE United States
  • Employees
  • AVTX N/A
  • SKYE N/A
  • Industry
  • AVTX Biotechnology: Pharmaceutical Preparations
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVTX Health Care
  • SKYE Health Care
  • Exchange
  • AVTX Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • AVTX 88.4M
  • SKYE 80.7M
  • IPO Year
  • AVTX 2015
  • SKYE N/A
  • Fundamental
  • Price
  • AVTX $7.35
  • SKYE $3.16
  • Analyst Decision
  • AVTX Strong Buy
  • SKYE Buy
  • Analyst Count
  • AVTX 4
  • SKYE 6
  • Target Price
  • AVTX $33.00
  • SKYE $18.67
  • AVG Volume (30 Days)
  • AVTX 54.4K
  • SKYE 214.0K
  • Earning Date
  • AVTX 03-28-2025
  • SKYE 02-25-2025
  • Dividend Yield
  • AVTX N/A
  • SKYE N/A
  • EPS Growth
  • AVTX N/A
  • SKYE N/A
  • EPS
  • AVTX N/A
  • SKYE N/A
  • Revenue
  • AVTX $820,000.00
  • SKYE N/A
  • Revenue This Year
  • AVTX N/A
  • SKYE N/A
  • Revenue Next Year
  • AVTX N/A
  • SKYE N/A
  • P/E Ratio
  • AVTX N/A
  • SKYE N/A
  • Revenue Growth
  • AVTX N/A
  • SKYE N/A
  • 52 Week Low
  • AVTX $4.18
  • SKYE $2.31
  • 52 Week High
  • AVTX $34.46
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • AVTX 42.79
  • SKYE 52.61
  • Support Level
  • AVTX $7.42
  • SKYE $2.60
  • Resistance Level
  • AVTX $8.50
  • SKYE $3.54
  • Average True Range (ATR)
  • AVTX 0.64
  • SKYE 0.48
  • MACD
  • AVTX 0.02
  • SKYE 0.03
  • Stochastic Oscillator
  • AVTX 17.16
  • SKYE 34.73

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: